The Japanese pharma company Eisai is  doubling down on its efforts to find new dementia drugs — and opening a new dementia-focused startup incubator.

The company is creating the incubator as part of its plan to move its Massachusetts-based research staff from Andover, Mass., to Cambridge, Mass., on May 20. As in Andover, the staff at the Cambridge facility will focus on finding new drugs targeting inflammation in the brain; some studies have shown a link between inflammation and dementia. Accordingly, the new Cambridge center is referred to as the Eisai Center for Genetics Guided Dementia Discovery or G2D2; the incubator itself will be called the Eisai Incubator for NeuroDiscovery, or e-IND.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy